



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade:	130.29
Trade Time:	4:00 PM ET Aug 22, 2017
Change:	2.86 (2.244%)
Day Range	128.14 - 130.73
52-Week Range	96.93 - 139.00
Volume	2,797,496

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID<sup>®</sup>, VIDAZA<sup>®</sup>, THALOMID<sup>®</sup>, POMALYST<sup>®</sup>/IMNOVID<sup>®</sup>, ABRAXANE<sup>®</sup>, OTEZLA<sup>®</sup>, ISTODAX<sup>®</sup> and IDHIFA<sup>®</sup>. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

- Aug 1, 2017*  
[FDA Grants Approval of IDHIFA<sup>®</sup> the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)
- Jul 28, 2017*  
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)
- Jul 27, 2017*  
[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)
- Jul 25, 2017*  
[Celgene Corporation Announces Settlement of Civil Litigation](#)
- Jul 5, 2017*  
[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

## Financials [\[ View all \]](#)

- Feb 10, 2017*  
[Annual Report \(10-K\)](#)
- Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)
- Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)
- Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)
- Oct 27, 2016*  
[Quarterly Report \(10-Q\)](#)